O11 biomedical
Last verified 2026-06-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.7Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2024-02-01attributed |
| Founded | 2022 |
| Headquarters | DE |
| Industry | medtech |
| Stage | unknown |
| Website | o11-biomedical.com |
Enteral CO2 absorption therapy (RESPILIQ) for hypercapnic lung failure — EIC Accelerator
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-02-01 | grant | $2.7M | undisclosed |
Detected tech stack
friendly-challenge, jquery, mywebsite, mywebsite creator, nginx, parallax.js, php
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | o11-biomedical.com, read 2026-06-07 |
| Description | self-reported | o11-biomedical.com, read 2026-06-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.